Screener
Xenon Pharmaceuticals XENE Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Other income: | ||||
| Interest income | 12,145 | 7,199 | 19,052 | 15,282 |
| Foreign exchange gain (loss) | (311) | 1,698 | 237 | 1,733 |
| Total other income | 11,834 | 8,897 | 19,289 | 17,015 |
| Loss before income taxes | (111,321) | (85,332) | (216,194) | (149,952) |
| Income tax recovery | 585 | 626 | 3,156 | 199 |
| Net loss | $(110,736) | $(84,706) | $(213,038) | $(149,753) |
| Other comprehensive income (loss): |
Item 1. Financial Statements
FAQ
- What is Xenon Pharmaceuticals's other income (expense)?
- Xenon Pharmaceuticals (XENE) reported other income (expense) of $11.83M in Q2 2026.
- How has Xenon Pharmaceuticals's other income (expense) changed year-over-year?
- Xenon Pharmaceuticals's other income (expense) increased by 33.0% year-over-year, from $8.9M to $11.83M.
- What is the long-term trend for Xenon Pharmaceuticals's other income (expense)?
- Over 3 years (2022 to 2025), Xenon Pharmaceuticals's other income (expense) has grown at a 93.5% compound annual growth rate (CAGR), from $3.89M to $28.18M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Xenon Pharmaceuticals's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude